CytomX Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 119.24K shares.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 174.00K shares.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 109.42K shares.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 158.53K shares.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 319.86K shares, a 141.67% increase from fiscal 2024.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 132.35K shares, a 700.43% increase from fiscal 2023.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 16.54K shares, a 83.82% decline from fiscal 2022.
- CytomX Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 102.22K shares, a 80.66% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 119.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 561.19K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 174.00K shares 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 109.42K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 319.86K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 158.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 132.35K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 132.35K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 12.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 132.35K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 119.87K shares 10-Q · filed 2024-05-08 | 136.41K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 16.54K shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 17.77K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 16.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 17.77K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | 96.62K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 1.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 102.22K shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 145.90K shares derived: sum of 4 quarters · filed 2023-03-27 |
| 2022-06-30 | 95.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 238.01K shares derived: sum of 4 quarters · filed 2023-03-27 |
| 2022-03-31 | 5.60K shares 10-Q · filed 2022-05-05 | 211.59K shares derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-12-31 | 44.91K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | 528.50K shares 10-K/A · filed 2023-03-27 |
| 2021-09-30 | 92.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 920.42K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 68.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 861.64K shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 322.51K shares 10-Q · filed 2021-05-06 | 991.81K shares derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | 436.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | 1.06M shares 10-K · filed 2021-02-24 |
| 2020-09-30 | 33.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 662.73K shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | 199.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 652.03K shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 395.53K shares 10-Q · filed 2020-05-07 | 468.01K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 34.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 146.93K shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 22.63K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 154.04K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | 15.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 249.56K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | 74.44K shares 10-Q · filed 2019-05-09 | 322.69K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | 41.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 673.38K shares 10-K · filed 2020-02-27 |
| 2018-09-30 | 118.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 833.86K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | 88.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | 971.83K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | 425.14K shares 10-Q · filed 2018-05-09 | 960.94K shares derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | 202.32K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 764.58K shares 10-K · filed 2020-02-27 |
| 2017-09-30 | 256.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 628.04K shares derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | 77.36K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 577.39K shares derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | 228.77K shares 10-Q · filed 2017-05-05 | 601.57K shares derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | 65.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | 414.40K shares 10-K · filed 2019-02-27 |
| 2016-09-30 | 205.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | 424.41K shares derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | 101.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | |
| 2016-03-31 | 41.60K shares 10-Q · filed 2016-05-06 | |
| 2015-12-31 | 75.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | 173.93K shares 10-K · filed 2018-03-07 |
| 2014-12-31 | 6.01K shares 10-K · filed 2017-03-02 | |
| 2013-12-31 | 53.19K shares 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |